Evommune is a clinical-stage biotechnology company developing therapies that target key drivers of chronic immune-mediated inflammation. Early clinical programs address chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis with candidates such as EVO756 and EVO301. The focus is on improving day-to-day disease control and reducing long-term damage from uncontrolled inflammation where existing options fall short.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | -22.2 | — |
| Q3 2025 | 10 | — | -12.5 | — |
| Q4 2025 | 0 | — | -28.3 | — |
| Q1 2026 | 0 | — | -21.7 | — |
| Q2 2026 | 0 | — | -32.3 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: MBIA Inc. (MBI), SEACOR Marine Holdings Inc. (SMHI), ADC Therapeutics SA (ADCT), Disciplined Growth Acquisition Corporation (DGAC), B&G Foods, Inc. (BGS), SmartRent, Inc. (SMRT)